|
1）Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci. 2013; 34: 340-6
|
|
|
|
2）Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A. 1994; 91: 9926-30
|
|
|
|
|
|
3）Itoh K, Igarashi K, Hayashi N, et al. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol Cell Biol. 1995; 15: 4184-93
|
|
|
|
|
|
4）Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236: 313-22
|
|
|
|
|
|
5）Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999; 13: 76-86
|
|
|
|
|
|
6）Tong KI, Katoh Y, Kusunoki H, et al. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol. 2006; 26: 2887-900
|
|
|
|
|
|
7）Kobayashi A, Kang MI, Watai Y, et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol. 2006; 26: 221-9
|
|
|
|
|
|
8）Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal. 2010; 13: 1665-78
|
|
|
|
|
|
9）Hirotsu Y, Katsuoka F, Funayama R, et al. Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res. 2012; 40: 10228-39
|
|
|
|
|
|
10）Lekawanvijit S, Kompa AR, Wang BH, et al. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res. 2012; 111: 1470-83
|
|
|
|
|
|
11）Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010; 6: 667-78
|
|
|
|
|
|
12）Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006; 17: 17-25
|
|
|
|
|
|
13）Henique C, Tharaux PL. Targeting signaling pathways in glomerular diseases. Curr Opin Nephrol Hypertens. 2012; 21: 417-27
|
|
|
|
|
|
14）Zoja C, Benigni A, Remuzzi G. The Nrf2 pathway in the progression of renal disease. Nephrol Dial Transplant. 2013 Jun 11. [Epub ahead of print]
|
|
|
|
|
|
15）Thornalley PJ, Rabbani N. Dietary and synthetic activators of the antistress gene response in treatment of renal disease. J Ren Nutr. 2012 ; 22: 195-202
|
|
|
|
|
|
16）Okawa H, Motohashi H, Kobayashi A, et al. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun. 2006; 339: 79-88
|
|
|
|
|
|
17）Yoh K, Itoh K, Enomoto A, et al. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int. 2001; 60: 1343-53
|
|
|
|
|
|
18）Jiang T, Tian F, Zheng H, et al. Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-kappaB-mediated inflammatory response. Kidney Int. 2013 Sep 11. [Epub ahead of print]
|
|
|
|
|
|
19）Cordova EJ, Velazquez-Cruz R, Centeno F, et al. The NRF2 gene variant, -653G/A, is associated with nephritis in childhood-onset systemic lupus erythematosus. Lupus. 2010; 19: 1237-42
|
|
|
|
|
|
20）Liu M, Grigoryev DN, Crow MT, et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int. 2009; 76: 277-85
|
|
|
|
|
|
21）Liu M, Reddy NM, Higbee EM, et al. The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia–reperfusion injury in mice. Kidney Int. 2014; 85: 133-41
|
|
|
|
|
|
22）Wu QQ, Wang Y, Senitko M, et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am J Physiol Renal Physiol. 2011; 300: F1180-92
|
|
|
|
|
|
23）Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73: 994-1007
|
|
|
|
|
|
24）Aleksunes LM, Goedken MJ, Rockwell CE, et al. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther. 2010; 335: 2-12
|
|
|
|
|
|
25）Shelton LM, Park BK, Copple IM. Role of Nrf2 in protection against acute kidney injury. Kidney Int. 2013; 84: 1090-5
|
|
|
|
|
|
26）Yoh K, Hirayama A, Ishizaki K, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells. 2008; 13: 1159-70
|
|
|
|
|
|
27）Jiang T, Huang Z, Lin Y, et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes. 2010; 59: 850-60
|
|
|
|
|
|
28）Aleksunes LM, Reisman SA, Yeager RL, et al. Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice. J Pharmacol Exp Ther. 2010; 333: 140-51
|
|
|
|
|
|
29）Chartoumpekis DV, Ziros PG, Psyrogiannis AI, et al. Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes. 2011; 60: 2465-73
|
|
|
|
|
|
30）Xue P, Hou Y, Chen Y, et al. Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes. 2013; 62: 845-54
|
|
|
|
|
|
31）Xu J, Kulkarni SR, Donepudi AC, et al. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes. 2012; 61: 3208-18
|
|
|
|
|
|
32）Uruno A, Furusawa Y, Yagishita Y, et al. The Keap1-Nrf2 system prevents onset of diabetes mellitus. Mol Cell Biol. 2013; 33: 2996-3010
|
|
|
|
|
|
33）Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011; 16: 123-40
|
|
|
|
|
|
34）Adam J, Hatipoglu E, O’Flaherty L, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011; 20: 524-37
|
|
|
|
|
|
35）Ooi A, Dykema K, Ansari A, et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res. 2013; 73: 2044-51
|
|
|
|
|
|
36）Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45: 860-7
|
|
|
|
|
|
37）Hong DS, Kurzrock R, Supko JG, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012; 18: 3396-406
|
|
|
|
|
|
38）Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011; 365: 327-36
|
|
|
|
|
|
39）Reisman SA, Chertow GM, Hebbar S, et al. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol. 2012; 23: 1663-73
|
|
|
|
|
|
40）Zhang DD. Bardoxolone brings Nrf2-based therapies to light. Antioxid Redox Signal. 2013; 19: 517-8
|
|
|
|
|
|
41）de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxdone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013; 369: 2492-503
|
|
|
|
|
|
42）Himmelfarb J, Tuttle KR, et al. New therapies for diabetic kidney disease. N Engl J Med. 2013; 369: 2549-50
|
|
|
|
|
|
43）Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367: 1098-107
|
|
|
|
|
|
44）Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012; 367: 1087-97
|
|
|
|
|
|
45）Oh CJ, Kim JY, Choi YK, et al. Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling. PloS One. 2012; 7: e45870
|
|
|
|
|